Literature DB >> 378370

Cisplatin (cis-diamminedichloroplatinum II).

A W Prestayko, J C D'Aoust, B F Issell, S T Crooke.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 378370     DOI： 10.1016/s0305-7372(79)80057-2

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  97 in total

1.  Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction.

Authors:  Xue Xue; Song You; Qiang Zhang; Yan Wu; Guo-Zhang Zou; Paul C Wang; Yu-Liang Zhao; Yan Xu; Lee Jia; Xiaoning Zhang; Xing-Jie Liang
Journal:  Mol Pharm       Date:  2012-02-13       Impact factor: 4.939

2.  Determination of cis-diamminedichloroplatinum (II) in plasma proteins and hemoglobin of cancer patients.

Authors:  R Mustonen; P Hietanen; S Leppälä; M Takala; K Hemminki
Journal:  Arch Toxicol       Date:  1989       Impact factor: 5.153

Review 3.  Cancer chemotherapy: past, present, and future--Part I.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1984-08       Impact factor: 1.798

4.  Interaction between cisplatin and mesna in mice.

Authors:  R T Dorr; K Lagel
Journal:  J Cancer Res Clin Oncol       Date:  1989       Impact factor: 4.553

Review 5.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

Authors:  Abolfazl Avan; Tjeerd J Postma; Cecilia Ceresa; Amir Avan; Guido Cavaletti; Elisa Giovannetti; Godefridus J Peters
Journal:  Oncologist       Date:  2015-03-12

6.  Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.

Authors:  F F Farris; F G King; R L Dedrick; C L Litterst
Journal:  J Pharmacokinet Biopharm       Date:  1985-02

7.  Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice.

Authors:  K Kawaida; K Matsumoto; H Shimazu; T Nakamura
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

8.  Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes.

Authors:  Z H Siddik; S al-Baker; G Thai; A R Khokhar
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma.

Authors:  P K Buamah; A Howell; H Whitby; E S Harpur; A Gescher
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  ATP11B mediates platinum resistance in ovarian cancer.

Authors:  Myrthala Moreno-Smith; J B Halder; Paul S Meltzer; Tamas A Gonda; Lingegowda S Mangala; Rajesha Rupaimoole; Chunhua Lu; Archana S Nagaraja; Kshipra M Gharpure; Yu Kang; Cristian Rodriguez-Aguayo; Pablo E Vivas-Mejia; Behrouz Zand; Rosemarie Schmandt; Hua Wang; Robert R Langley; Nicholas B Jennings; Cristina Ivan; Jeremy E Coffin; Guillermo N Armaiz; Justin Bottsford-Miller; Sang Bae Kim; Margaret S Halleck; Mary J C Hendrix; William Bornman; Menashe Bar-Eli; Ju-Seog Lee; Zahid H Siddik; Gabriel Lopez-Berestein; Anil K Sood
Journal:  J Clin Invest       Date:  2013-04-15       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.